French Regulators Clear Anteris' Duravr Heart Valve for Global Trial
AVR has more than doubled off its 52-week low of $2.85.
Summary
Anteris Technologies has secured French regulatory clearance to begin a global trial for its Duravr Transcatheter Heart Valve. This is a significant positive step, allowing the company to expand its clinical development efforts into a key European market. The clearance validates the company's investment in its pipeline, following recent capital raises including a $320 million raise reported in Q1 2026 and a $250 million ATM offering finalized in late May, both aimed at funding product advancement.
At the time of this announcement, AVR was trading at $9.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $938.4M. The 52-week trading range was $2.85 to $10.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.